



CERTIFICATE OF MAILING		
I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.		
Typed or Printed Name	Cindy Hoang	
Signature	Date 11/8/02	
<b>RESPONSE TO RESTRICTION REQUIREMENT</b>  Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket (Confirmation No.)	UCAL217 7367
	First Named Inventor	Y. Huang
	Application Number	10/033,526
	Filing Date	November 2, 2001
	Group Art Unit	1647
	Examiner Name	C.J. Nichols
	Title:	Methods of treating disorders related to apoE

RECEIVED  
NOV 21 2002  
TECH CENTER 1600/2900  
#7  
12/4/02

Sir:

This is in response to the Restriction Requirement dated September 11, 2002. The Restriction Requirement set forth a one-month time period for response, making a response due on or before November 11, 2002. Accordingly, this response is timely filed.

#### I. REMARKS

#### RESTRICTION REQUIREMENT

In the Restriction Requirement, the Office Action made two restriction requirements, as follows:

##### 1) Claim groups

The Office Action required election of one of the following groups of claims:

- Group I: Claims 1-6, 23-24, 28, and 31, drawn to a method of inhibiting formation of neurofibrillary tangles in an individual said method comprising reducing formation of a carboxyl-truncated form of apoE;
- Group II: Claims 7-11, drawn to a transgenic non-human animal;
- Group III: Claims 12-16, drawn to a method of screening for biologically active agents;
- Group IV: Claims 17-20, drawn to an isolated cell comprising a nucleic acid molecule that comprises a nucleotide sequence that encodes a carboxyl-terminal truncated form of apoE;
- Group V: Claims 21 and 22, drawn to a method of inhibiting formation of neurofibrillary tangles in an individual, the method comprising inhibiting interaction of carboxyl-terminal truncated form of apoE with other components of neurofibrillary tangle;
- Group VI: Claim 26, drawn to a method of treating Alzheimer's disease the method of comprising assaying for the presence of carboxyl-terminal truncated apoE in a neuronal cell and